Limitations and Potentials of In Vitro Sensitivity Testing of Human Small Cell Carcinoma of the Lung

  • Henrik Roed
  • Lars L. Vindeløv
  • Mogens Spang-Thomsen
  • Svend Aa. Engelholm
Part of the Cancer Treatment and Research book series (CTAR, volume 28)


The clonogenic assay has been proposed both as a tool for individually guided chemotherapy and as a preclinical drug evaluation system. Because tumor cells are heterogeneous it is unlikely that a test where only a minor fraction of the cells is tested can predict the sensitivity of all tumor cells in the patient. The pronounced negative accuracy reported can be explained on the basis of the patient populations being studied. The technical limitations of the test are presented, and it is concluded that with the present status of the test, it is only suited as a preclinical test system.

It is suggested that in vitro sensitivity testing of drugs in a panel of cell lines established from patients with small cell carcinoma of the lung might help to identify drugs that could alter the clinical course of the disease.


Clonogenic Assay Sensitivity Pattern Continuous Cell Line Human Small Cell Lung Cancer Human Tumor Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD: Small Cell Lung Cancer 1973–1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515–539, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    Hamburger AW: Use of in vitro tests in predictive cancer chemotherapy. J Natl Cancer Inst 66:981–988, 1981.PubMedGoogle Scholar
  3. 3.
    Roper PR, Drewinko B: Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36:2182–2188, 1976.PubMedGoogle Scholar
  4. 4.
    Puck TT, Marcus PI: Action of X-rays on mammalian cells. J Exp Med 103:653–666, 1956.PubMedCrossRefGoogle Scholar
  5. 5.
    Salmon SE. Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH: Chemosensitivity testing of human solid tumors. Cancer 53:1240–1245, 1984.PubMedCrossRefGoogle Scholar
  7. 7.
    Makuch RW: Interpreting clonogenic assay results. Lancet, ii: 438, 1982.CrossRefGoogle Scholar
  8. 8.
    Vecchio TJ: Predictive value of a single diagnostic test in unselected populations. N Engl J Med 274:1171–1173, 1966.PubMedCrossRefGoogle Scholar
  9. 9.
    Poste G, Greig R: The experimental and clinical implications of cellular heterogeneity in malignant tumors. J Cancer Res Clin Oncol 106:159–170, 1983.PubMedCrossRefGoogle Scholar
  10. 10.
    Vindeløv L, Hansen HH, Spang-Thomsen M: Growth characteristics and heterogeneity of small cell carcinoma of the lung. In: Recent results in Cancer Research, Seeber, S (ed.), 97, pp 47–54. Springer-Verlag, Berlin, Heidelberg, 1985.Google Scholar
  11. 11.
    Talmadge JE, Benedict K, Madsen J, Fidler IJ: Development of biological diversity and susceptibility to chemotherapy in murine cancer metastases. Cancer Res 44:3801–3805, 1984.PubMedGoogle Scholar
  12. 12.
    Anonymous: Clonogenic assays for the chemotherapeutic sensitivity of human tumours. Lancet, i: 780–781, 1982.Google Scholar
  13. 13.
    Woodruff MFA: Cellular heterogeneity in tumours. Br J Cancer 47:589–594, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Selby P, Buick RN, Tannock I: A critical appraisal of the ‘human tumor stem-cell assay’. N Engl J Med 308:129–134, 1983.PubMedCrossRefGoogle Scholar
  15. 15.
    Carney DN, Broder L, Edelstein M, Gazdar A, Hansen M, Havemann K, Matthews MJ, Sorenson GD, Vindeløv L: Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep 67:27–35, 1983.PubMedGoogle Scholar
  16. 16.
    Umbach G, Spitzer G, Drewinko B: ‘Clumpogenic’ v clonogenic assay. Lancet ii: 628, 1983.Google Scholar
  17. 17.
    Agrez MV, Kovach JS, Lieber MM: Cell aggregates in the soft agar ‘human tumour stem-cell assay’. Br J Cancer 46:880–887, 1982.PubMedCrossRefGoogle Scholar
  18. 18.
    Engelholm SAa, Spang-Thomsen M, Brünner N, Nøhr I, Vindeløv LL: Disaggregation of human solid tumours by combined mechanical and enzymatic methods. Br J Cancer: 51:93–98, 1985.PubMedCrossRefGoogle Scholar
  19. 19.
    Rasey JS, Nelson NJ: Response of an in vivo-in vitro tumour to X-rays and cytotoxic drugs: effect of tumour disaggregation method on cell survival. Br J Cancer 41/suppl 4:217–221, 1980.Google Scholar
  20. 20.
    Mann BD, Kern DH, Giuliano AE, Burk MW, Campbell MA, Kaiser LR, Morton DL: Clinical correlations with drug sensitivities in the clonogenic assay. Arch Surg 117:33–36, 1982.PubMedGoogle Scholar
  21. 21.
    Kaufmann M, Mattern J, Volm M, Hohorst HJ, Peter G, Voelcker G: In vitro testing of cyclophosphamide on tumors. Naturwissenschaften 62:446–447, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Shrivastav S, Stone KR, Paulson DF, Bonar RA: Activation of cyclophosphamide for in vitro testing of cell sensitivity. Cancer Res 40:4443–4445, 1980.PubMedGoogle Scholar
  23. 23.
    Fry JR, Bridges JW: A novel mixed hepatocyte-fibroblast culture system and its use as a test for metabolism-mediated cytotoxicity. Biochem Pharm 26:969–973, 1977.PubMedCrossRefGoogle Scholar
  24. 24.
    Alberts DS, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA: Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:253–264, 1981.PubMedGoogle Scholar
  25. 25.
    Van Putten LM, Lelieveld P: The effects of cytostatic drugs and radiotherapy on the cell cycle. In: Scientific foundations of oncology, Symington T, Carter RL (eds.). William Heinemann Medical Books Ltd, London, pp 136–145, 1976.Google Scholar
  26. 26.
    Van Putten LM: Are cell kinetic data relevant for the design of tumour chemotherapy schedules? Cell Tissue Kinet 7:493–504, 1974.PubMedGoogle Scholar
  27. 27.
    Hill BT, Price LA: An experimental biological basis for increasing the therapeutic index of clinical cancer therapy. Ann NY Acad Sci 397:72–87, 1982.PubMedCrossRefGoogle Scholar
  28. 28.
    Puck TT, Marcus PI: A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: The use of X-irradiated cells to supply conditioning factors. Proc Natl Acad Sci USA 41:432–437, 1955.PubMedCrossRefGoogle Scholar
  29. 29.
    Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977.PubMedCrossRefGoogle Scholar
  30. 30.
    Tveit KM, Endresen L, Rugstad HE, Fodstad Ø, Pihl A: Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: Malignant melanomas. Br J Cancer 44:539–544, 1981.PubMedCrossRefGoogle Scholar
  31. 31.
    Engelholm SAa, Spang-Thomsen M, Brünner N, Nøhr I, Roed H, Vindeløv L: In vitro culturing of tumor cells on soft agar. In: Human tumor cloning, Salmon SE, Trent JM (eds.), Grune & Stratton, New York, pp 197–203, 1984.Google Scholar
  32. 32.
    Hill BT, Whelan DH: Attempts to optimise colony-forming efficiencies using three different survival assays and a range of human tumour continuous cell lines. Cell Biol Int Rep 7:617–624, 1983.PubMedCrossRefGoogle Scholar
  33. 33.
    Barnes D, Sato G: Methods for growth of cultured cells in serum-free medium. Analytical Biochem 102:255–270, 1980.CrossRefGoogle Scholar
  34. 34.
    Carney DN, Bunn PA, Gazdar AF, Pagan JA, Minna JD: Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci USA 78:3185–3189, 1981.PubMedCrossRefGoogle Scholar
  35. 35.
    Lechner JF, Haugen Aa, McClendon IA, Pettis EW: Clonal growth of normal adult human bronchial epithelial cells in a serum-free medium. In vitro 18:633–642, 1982.PubMedCrossRefGoogle Scholar
  36. 36.
    Cowan DH, Graham J: Stimulation of human tumor colony formation by platelet lysate. J Lab Clin Med 102:973–986, 1983.PubMedGoogle Scholar
  37. 37.
    Engelholm SAa, Spang-Thomsen M, Vindelov LL: A short-term in vitro test for tumour sensitivity to adriamycin based on flow cytometric DNA analysis. Br J Cancer 47:497–502, 1983.PubMedCrossRefGoogle Scholar
  38. 38.
    Meyskens FL, Thomson SP, Moon TE: Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res 44:271–277,Google Scholar
  39. 39.
    Kressner BE, Morton RRA, Martens AE, Salmon SE, Von Hoff DD, Soehnlen B: Use of an image analysis system to count colonies in stem cell assays of human tumors. In: Cloning of human tumor stem cells. Salmon SE (ed.), Alan R Liss, New York, pp 179–193, 1980.Google Scholar
  40. 40.
    Salmon SE: Human tumor colony assay and chemosensitivty testing. Cancer Treat Rep 68:117–125, 1984.PubMedGoogle Scholar
  41. 41.
    Von Hoff DD: ‘Send this patient’s tumor for culture and sensitivity’. N Engl J Med 308:154–155, 1983.CrossRefGoogle Scholar
  42. 42.
    Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW, Cate CC, Maurer LH: Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 45:906–918, 1980.PubMedCrossRefGoogle Scholar
  43. 43.
    Gazdar AF, Carney DN, Russell EK, Sims HL, Baylin SB, Bunn PA, Guccion JG, Minna JD: Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 40:3502–3507, 1980.PubMedGoogle Scholar
  44. 44.
    Kolata G: Cell biology yields clues to lung cancer. Science 218:38–39, 1982.PubMedCrossRefGoogle Scholar
  45. 45.
    Jiang TL, Liu RH, Salmon SE: Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemother Pharmacol 11:1–4, 1983.PubMedCrossRefGoogle Scholar
  46. 46.
    Kisner DL, Mehta P, Paget GE, Von Hoff DD: Activity of Carbetimer in a human tumor cloning system. Investigational New Drugs 2:55–58, 1984.PubMedCrossRefGoogle Scholar
  47. 47.
    Roed H, Vindeløv LL, Christensen IJ, Hansen HH, Spang-Thomsen M: Comparison of the potential of the 2 epipodophyllotoxin derivatives VP-16 and VM-26 on small cell cancer of the lung cell lines. Proc Am Assoc Cancer Res 26:1315, 1985.Google Scholar
  48. 48.
    Carney DN, Mitchell JB, Kinsella TJ: In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. Cancer Res 43:2806–2811, 1983.PubMedGoogle Scholar
  49. 49.
    Wang-Peng J, Kao-Shun CS, Lee EC, Bunn PA, Carney DN, Gjazdar AF, Minna JD: A specific chromosome defect associated with human small cell lung cancer: deletion 3 p (14–23). Science 215:181–183, 1982.CrossRefGoogle Scholar
  50. 50.
    Weisenthal LM: In vitro assays in preclinical antineoplastic drug screening. Semin Oncol 8:362–376, 1981.PubMedGoogle Scholar
  51. 51.
    Tveit KM, Fostad Ø, Pihl A: The usefulness of human tumor cell lines in the study of chemosensitivity. A study of malignant melanomas. Int J Cancer 28:403–408, 1981.PubMedCrossRefGoogle Scholar
  52. 52.
    Anonymous: Testing anti-cancer drugs. Lancet 1972, i:827–828, 1972.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Henrik Roed
  • Lars L. Vindeløv
  • Mogens Spang-Thomsen
  • Svend Aa. Engelholm

There are no affiliations available

Personalised recommendations